参考文献: [1]Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316 [2]Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. J Gastrointest Oncol. 2017 Apr;8(2):E32-E38. [3]Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. Exp Hematol Oncol. 2017 Jan 10;6:1. [4]Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2015 Oct 23;108(2). pii: djv310 [5]A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Onco Targets Ther. 2015 Dec 1;8:3561-4. |
|
来自: ccchengphd > 《Cancer》